Anzeige
Mehr »
Samstag, 19.07.2025 - Börsentäglich über 12.000 News
Kupfer en mass...: 10 Prozent-Kupfer an der Oberfläche! - Diese Entdeckung könnte zur heißesten Kupferstory des Jahres werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
18.07.25 | 16:01
15,100 Euro
+1,34 % +0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,90015,20018.07.
14,80015,00018.07.

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrJPM Favors AKESO/INNOVENT BIO/HENGRUI PHARMA as CN Healthcare Sector Rebounds Sharply This Yr16
MiAkeso, Inc.: Akeso Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer65HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...
► Artikel lesen
AKESO Aktie jetzt für 0€ handeln
04.07.HSI Closes at 23,916, Down 153 pts; HSTI Closes at 5,216, Down 17 pts; ALI HEALTH Down over 6%; CCB, J&T EXPRESS-W, AKESO, MINSHENG BANK, XD INC Hit New Highs; Market Turnover Rises9
04.07.HSI Closes Midday at 23,921, Down 148 pts; HSTI Closes Midday at 5,209, Down 24 pts; ALI HEALTH Down over 6%; AKESO, KB LAMINATES Hit New Highs5
03.07.HSI Closes at 24,069, Down 151 pts; HSTI Closes at 5,233, Down 35 pts; XIAOMI Down over 3%; ZIJIN MINING, AKESO, KB LAMINATES, ASCENTAGE, GLOBAL NEW MAT Hit New Highs; Market Turnover Rises15
03.07.Akeso, Inc.: Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy140HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its...
► Artikel lesen
30.06.AKESO (09926): POLL RESULTS OF THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, JUNE 30, 202510
16.06.Akeso, Inc.: Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025420HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16...
► Artikel lesen
11.06.AKESO (09926): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 20252
11.06.AKESO (09926): NOTICE OF EXTRAORDINARY GENERAL MEETING2
11.06.AKESO (09926): PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO DR. XIA AND NOTICE OF EXTRAORDINARY GENERAL MEETING1
05.06.Akeso gains NMPA approval for cadonilimab to treat cervical cancer14
05.06.Akeso's Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment1
05.06.AKESO (09926): VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER2
04.06.JPMorgan senkt Kursziel für Akeso wegen US-Regulierungsbedenken7
04.06.JPMorgan lowers Akeso stock price target due to US regulatory concerns2
30.05.Akeso, Summit's ivonescimab delayed progression by 48% in certain lung cancers in first global phase 3 readout9
26.05.AKESO (09926): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS1
14.05.DelveInsight Business Research, LLP: Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight661The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes...
► Artikel lesen
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF ...-
Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3